Genaro Rodriguez-Uribe

Dr. Genaro Rodriguez-Uribe

Facultad de Medicina y Psicología, Universidad Autónoma de Baja California
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Sports
Verified
Journal Article
Open access
PDF file
ARArnulfo Ramos-Jiménez
Arnulfo Ramos-Jiménez
RHRosa Patricia Hernández-Torres
Rosa Patricia Hernández-Torres
DHDAVID ALFREDO HERNANADEZ-ONTIVEROS
DAVID ALFREDO HERNANADEZ-ONTIVEROS
MOMelinna Ortiz-Ortiz
Melinna Ortiz-Ortiz
Reymond Josue Lopez-FregosoReymond Josue Lopez-Fregoso
Reymond Josue Lopez-Fregoso
Marco Antonio Hernández-LepeMarco Antonio Hernández-Lepe
Marco Antonio Hernández-Lepe
Glycine, the simple amino acid, is a key component of muscle metabolism with proven cytoprotective effects and hypothetical benefits as a therapeutic nutrient. Cell, in vitro, and animal studies suggest that glycine enhances protection against muscle wasting by activating anabolic pathways and inhibiting proteolytic gene expression. Some evidence indicates that glycine supplementation may enhance peak power output, reduce lactic acid accumulation during high-intensity exercise, and improve sleep quality and recovery. This literature review critically explores glycine’s potential as an ergogenic aid and its relevance to muscle regeneration, muscle strength, endurance exercise performance, and sleep quality. It also underscores key areas for future research. It is concluded that more randomized controlled clinical trials in humans are needed to confirm glycine’s potential as a dietary supplement to support muscle function, recovery, and overall athletic performance as an ergogenic aid and to establish nutritional recommendations for athletic performance. Also, it is essential to consider that high doses (>500 mg/kg of body mass) could induce cytotoxic effects and contribute to acute glutamate toxicity.

1 October 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
JHJennifer Hernández-Juárez
Jennifer Hernández-Juárez
Genaro Rodriguez-UribeGenaro Rodriguez-Uribe
Genaro Rodriguez-Uribe
SBShyamanga R Borooah
Shyamanga R Borooah
Inherited retinal dystrophies [IRDs] are a common cause of severe vision loss resulting from pathogenic genetic variants. The eye is an attractive target organ for testing clinical translational approaches in inherited diseases. This has been demonstrated by the approval of the first gene supplementation therapy to treat an autosomal recessive IRD, RPE65-linked Leber congenital amaurosis (type 2), 4 years ago. However, not all diseases are amenable for treatment using gene supplementation therapy, highlighting the need for alternative strategies to overcome the limitations of this supplementation therapeutic modality. Gene editing has become of increasing interest with the discovery of the CRISPR-Cas9 platform. CRISPR-Cas9 offers several advantages over previous gene editing technologies as it facilitates targeted gene editing in an efficient, specific, and modifiable manner. Progress with CRISPR-Cas9 research now means that gene editing is a feasible strategy for the treatment of IRDs. This review will focus on the background of CRISPR-Cas9 and will stress the differences between gene editing using CRISPR-Cas9 and traditional gene supplementation therapy. Additionally, we will review research that has led to the first CRISPR-Cas9 trial for the treatment of CEP290-linked Leber congenital amaurosis (type 10), as well as outline future directions for CRISPR-Cas9 technology in the treatment of IRDs.

28 May 2021 in APMIS
Verified
Journal Article
Closed access
PDF file
RORodolfo Ocadiz‐Delgado
Rodolfo Ocadiz‐Delgado
NHNicolas Serafin Higuera
Nicolas Serafin Higuera
EAElizabeth Alvarez‐Rios
Elizabeth Alvarez‐Rios
EGEnrique García‐Villa
Enrique García‐Villa
MTManuel Tinajero‐Rodríguez
Manuel Tinajero‐Rodríguez
PGPatricio Gariglio
Patricio Gariglio

28 August 2020 in Molecules
Verified
Journal Article
Open access
PDF file
José de Jesús Manríquez TorresJosé de Jesús Manríquez Torres
José de Jesús Manríquez Torres
Marco Antonio Hernández-LepeMarco Antonio Hernández-Lepe
Marco Antonio Hernández-Lepe
JCJosé Román Chávez-Méndez
José Román Chávez-Méndez
SGSusana González-Reyes
Susana González-Reyes
ISIdanya R. Serafin-Higuera
Idanya R. Serafin-Higuera
Javier Martin-TorresJavier Martin-Torres
Javier Martin-Torres
In research on natural molecules with cytotoxic activity that can be used for the development of new anticancer agents, the cytotoxic activity of hexane, chloroform, and methanol extracts from the roots of Acacia schaffneri against colon, lung, and skin cancer cell lines was explored. The hexane extract showed the best activity with an average IC50 of 10.6 µg mL−1. From this extract, three diterpenoids, phyllocladan-16α,19-diol (1), phyllocladan-16α-ol (2), and phylloclad-16-en-3-ol (3), were isolated and characterized by their physical and spectroscopic properties. Diterpenoids 1 and 2 were tested against the same cancer cell lines, as well as their healthy counterparts, CCD841 CoN, MRC5, and VH10, respectively. Compound 1 showed moderate activity (IC50 values between 24 and 70 μg mL−1), although it showed a selective effect against cancer cell lines. Compound 2 was practically inactive. The cytotoxicity mechanism of 1 was analyzed by cell cycle, indicating that the compound induces G0/G1 cell cycle arrest. This effect might be generated by DNA alkylation damage. In addition, compound 1 decreased migration of HT29 cells.

1 July 2019 in Gene
Verified
Journal Article
Closed access
OCOscar F. Chacón-Camacho
Oscar F. Chacón-Camacho
ASAcatzin Salgado-Medina
Acatzin Salgado-Medina
NANayeli Alcaraz-Lares
Nayeli Alcaraz-Lares
DLDaniel López-Moreno
Daniel López-Moreno
TBTania Barragán-Arévalo
Tania Barragán-Arévalo
JZJuan Carlos Zenteno
Juan Carlos Zenteno

16 May 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Genaro Rodriguez-UribeGenaro Rodriguez-Uribe
Genaro Rodriguez-Uribe
NHNicolas Serafin Higuera
Nicolas Serafin Higuera
GDGabriela Damian-Morales
Gabriela Damian-Morales
ENOC MARIANO CORTÉS MALAGÓNENOC MARIANO CORTÉS MALAGÓN
ENOC MARIANO CORTÉS MALAGÓN
VGVicky García-Hernández
Vicky García-Hernández
José Bonilla-DelgadoJosé Bonilla-Delgado
José Bonilla-Delgado
Objective. This work aimed to determine if cataractous changes associated with EMT occurring in the K14E6 mice lenses are associated with TGF-βand Wnt/β-catenin signaling activation.Materials and Methods. Cataracts of K14E6 mice were analysed histologically; and components of TGF-βand Wnt/β-catenin signaling were evaluated by Western blot, RT-qPCR, in situ RT-PCR, IHC, or IF technics. Metalloproteinases involved in EMT were also assayed using zymography. The endogenous stabilisation of Smad7 protein was also assessed using an HDAC inhibitor.Results. The K14E6 mice, which displayed binocular cataracts in 100% of the animals, exhibited loss of tissue organisation, cortical liquefaction, and an increase in the number of hyperproliferative-nucleated cells with mesenchymal-like characteristics in the lenses. Changes in lenses’ cell morphology were due to actin filaments reorganisation, activation of TGF-βand Wnt/β-catenin pathways, and the accumulation of MTA1 protein. Finally, the stabilisation of Smad7 protein diminishes cell proliferation, as well as MTA1 protein levels.Conclusion. The HPV16-E6 oncoprotein induces EMT in transgenic mice cataracts. The molecular mechanism may involve TGF-βand Wnt/β-catenin pathways, suggesting that the K14E6 transgenic mouse could be a useful model for the study or treatment of EMT-induced cataracts.